Literature DB >> 30838674

NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia.

Hussein A Abbas1, Farhad Ravandi2, Sanam Loghavi3, Keyur P Patel3, Gautam Borthakur2, Tapan M Kadia2, Elias Jabbour2, Koichi Takahashi2, Jorge Cortes2, Ghayas C Issa2, Marina Konopleva2, Hagop M Kantarjian2, Nicholas J Short2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30838674      PMCID： PMC6602057          DOI： 10.1002/ajh.25454

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  5 in total

1.  Size of FLT3 internal tandem duplication has prognostic significance in patients with acute myeloid leukemia.

Authors:  Derek L Stirewalt; Kenneth J Kopecky; Soheil Meshinchi; Julia H Engel; Era L Pogosova-Agadjanyan; Jeremy Linsley; Marilyn L Slovak; Cheryl L Willman; Jerald P Radich
Journal:  Blood       Date:  2005-12-20       Impact factor: 22.113

2.  Genomic Classification and Prognosis in Acute Myeloid Leukemia.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Hartmut Döhner; Peter J Campbell; Lars Bullinger; Verena I Gaidzik; Peter Paschka; Nicola D Roberts; Nicola E Potter; Michael Heuser; Felicitas Thol; Niccolo Bolli; Gunes Gundem; Peter Van Loo; Inigo Martincorena; Peter Ganly; Laura Mudie; Stuart McLaren; Sarah O'Meara; Keiran Raine; David R Jones; Jon W Teague; Adam P Butler; Mel F Greaves; Arnold Ganser; Konstanze Döhner; Richard F Schlenk
Journal:  N Engl J Med       Date:  2016-06-09       Impact factor: 91.245

3.  A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.

Authors:  Elias Jabbour; Nicholas J Short; Farhad Ravandi; Xuelin Huang; Lianchun Xiao; Guillermo Garcia-Manero; William Plunkett; Varsha Gandhi; Koji Sasaki; Naveen Pemmaraju; Naval G Daver; Gautam Borthakur; Nitin Jain; Marina Konopleva; Zeev Estrov; Tapan M Kadia; William G Wierda; Courtney D DiNardo; Mark Brandt; Susan M O'Brien; Jorge E Cortes; Hagop Kantarjian
Journal:  Cancer       Date:  2017-07-14       Impact factor: 6.860

4.  High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML.

Authors:  Sanjay S Patel; Frank C Kuo; Christopher J Gibson; David P Steensma; Robert J Soiffer; Edwin P Alyea; Yi-Bin A Chen; Amir T Fathi; Timothy A Graubert; Andrew M Brunner; Martha Wadleigh; Richard M Stone; Daniel J DeAngelo; Valentina Nardi; Robert P Hasserjian; Olga K Weinberg
Journal:  Blood       Date:  2018-05-03       Impact factor: 22.113

5.  AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features.

Authors:  Claudia Haferlach; Cristina Mecucci; Susanne Schnittger; Alexander Kohlmann; Marco Mancini; Antonio Cuneo; Nicoletta Testoni; Giovanna Rege-Cambrin; Antonella Santucci; Marco Vignetti; Paola Fazi; Maria Paola Martelli; Torsten Haferlach; Brunangelo Falini
Journal:  Blood       Date:  2009-05-08       Impact factor: 22.113
  5 in total
  4 in total

1.  Blast phenotype and comutations in acute myeloid leukemia with mutated NPM1 influence disease biology and outcome.

Authors:  Emily F Mason; Robert P Hasserjian; Nidhi Aggarwal; Adam C Seegmiller; Olga Pozdnyakova
Journal:  Blood Adv       Date:  2019-11-12

2.  Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens.

Authors:  Curtis A Lachowiez; Sanam Loghavi; Tapan M Kadia; Naval Daver; Gautam Borthakur; Naveen Pemmaraju; Kiran Naqvi; Yesid Alvarado; Musa Yilmaz; Nicholas Short; Maro Ohanian; Sherry R Pierce; Keyur P Patel; Wei Qiao; Jing Ning; Koji Sasaki; Koichi Takahashi; Elias Jabbour; Michael Andreeff; Farhad Ravandi; Hagop M Kantarjian; Marina Konopleva; Courtney D DiNardo
Journal:  Blood Adv       Date:  2020-04-14

3.  A novel machine-learning-derived genetic score correlates with measurable residual disease and is highly predictive of outcome in acute myeloid leukemia with mutated NPM1.

Authors:  Nikhil Patkar; Anam Fatima Shaikh; Chinmayee Kakirde; Shrinidhi Nathany; Hridya Ramesh; Prasanna Bhanshe; Swapnali Joshi; Shruti Chaudhary; Sadhana Kannan; Syed Hasan Khizer; Gaurav Chatterjee; Prashant Tembhare; Dhanalaxmi Shetty; Anant Gokarn; Sachin Punatkar; Avinash Bonda; Lingaraj Nayak; Hasmukh Jain; Navin Khattry; Bhausaheb Bagal; Manju Sengar; Sumeet Gujral; Papagudi Subramanian
Journal:  Blood Cancer J       Date:  2019-10-01       Impact factor: 11.037

4.  The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML.

Authors:  Jennifer B Dunlap; Jessica Leonard; Mara Rosenberg; Rachel Cook; Richard Press; Guang Fan; Philipp W Raess; Brian J Druker; Elie Traer
Journal:  Am J Hematol       Date:  2019-06-21       Impact factor: 13.265
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.